Outcomes of Nononcology Accelerated Approvals (Reply)

Surrogate measures used for accelerated approval are, by definition, not fully validated and may lack strong evidence linking them to clinical benefit. The authors highlight recent cases where reliance on such surrogates led to regulatory withdrawals or ongoing uncertainty, and emphasize that while accelerated approval can speed access to new treatments, it also requires careful follow-up and realistic communication about risks.